White Arica, Thompson Trevor D, White Mary C, Sabatino Susan A, de Moor Janet, Doria-Rose Paul V, Geiger Ann M, Richardson Lisa C
MMWR Morb Mortal Wkly Rep. 2017 Mar 3;66(8):201-206. doi: 10.15585/mmwr.mm6608a1.
Healthy People 2020 (HP2020) includes objectives to increase screening for breast, cervical, and colorectal cancer (1) as recommended by the U.S. Preventive Services Task Force (USPSTF).* Progress toward meeting these objectives is monitored by measuring cancer screening test use against national targets using data from the National Health Interview Survey (NHIS) (1). Analysis of 2015 NHIS data indicated that screening test use remains substantially below HP2020 targets for selected cancer screening tests. Although colorectal cancer screening test use increased from 2000 to 2015, no improvements in test use were observed for breast and cervical cancer screening. Disparities exist in screening test use by race/ethnicity, socioeconomic status, and health care access indicators. Increased measures to implement evidence-based interventions and conduct targeted outreach are needed if the HP2020 targets for cancer screening are to be achieved and the disparities in screening test use are to be reduced.
《健康人民2020》(HP2020)包含了一些目标,即按照美国预防服务工作组(USPSTF)的建议,增加对乳腺癌、宫颈癌和结直肠癌的筛查(1)。* 通过使用来自国家健康访谈调查(NHIS)的数据,对照国家目标衡量癌症筛查测试的使用情况,来监测实现这些目标的进展(1)。对2015年NHIS数据的分析表明,某些癌症筛查测试的使用情况仍远低于HP2020的目标。尽管从2000年到2015年结直肠癌筛查测试的使用有所增加,但乳腺癌和宫颈癌筛查测试的使用情况并未得到改善。在筛查测试的使用方面,存在种族/民族、社会经济地位和医疗保健可及性指标方面的差异。如果要实现HP2020的癌症筛查目标并减少筛查测试使用方面的差异,就需要增加实施循证干预措施和进行有针对性的宣传推广的力度。